저작자표시-비영리-변경금지 2.0 대한민국

이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게

- 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.

다음과 같은 조건을 따라야 합니다:

저작자표시. 귀하는 원저작자를 표시하여야 합니다.

비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다.

변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다.

귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건을 명확하게 나타내어야 합니다.
저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.

저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다.

이것은 이용허락규약(Legal Code)을 이해하기 쉽게 요약한 것입니다.

Disclaimer
You are free to:

- **Share** — copy and redistribute the material in any medium or format

Under the following terms:

- **Attribution** — You must give [appropriate credit](https://creativecommons.org/licenses/by/2.0/), provide a link to the license, and [indicate if changes were made](https://creativecommons.org/licenses/by/2.0/). You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

- **NonCommercial** — You may not use the material for [commercial purposes](https://creativecommons.org/licenses/by/2.0/).

- **NoDerivatives** — If you [remix, transform, or build upon](https://creativecommons.org/licenses/by/2.0/) the material, you may not distribute the modified material.

You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.

This is a human-readable summary of (and not a substitute for) the [license](https://creativecommons.org/licenses/by/2.0/).
EVALUATION OF COMPARATIVE PHARMACOKINETICS AND BIOEQUIVALENCE OF A NEW ACECLOFENAC FORMULATION

Elena Ismatova¹, Jaeseong Oh¹, Kyung-Sang Yu¹, Bo-Hyung Kim², Sung-Vin Yim²

¹Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea

²Department of Clinical Pharmacology and Therapeutics, Kyung Hee University College of Medicine and Hospital, Seoul, Republic of Korea

Correspondence: Sung-Vin Yim, MD, PhD
Address for correspondence: Department of Clinical Pharmacology and Therapeutics, Kyung Hee University College of Medicine and Hospital, 23 Kyung Hee Daero Dongdaemun-gu, Seoul 130-872, Republic of Korea
Tel: 82-2-958-9567
Fax: 82-10-3736-4398
Email: ysvin@khu.ac.kr
Abstract

Afenac® is a new generic formulation of aceclofenac, a commonly used nonsteroidal anti-inflammatory drug (NSAID) for treating pain of various origins, including inflammatory, degenerative, joint, and musculoskeletal diseases. We compared the pharmacokinetic (PK) properties and evaluated the bioequivalence of two formulations of aceclofenac 100 mg tablets. A single-dose, randomized, 2 × 2 crossover study was performed with 23 healthy Korean male subjects. The subjects randomly received 100 mg of either the test formulation (Afenac®, Korea Arlico Pharm, Seoul, Korea) or the reference formulation (Airtal®, Dae Woong Co., Ltd., Seoul, Korea). After a 1-week washout period, the subjects received the other formulation. Aceclofenac plasma concentrations were determined using the validated high-performance liquid chromatography coupled with tandem mass spectrometry, and pharmacokinetic (PK) parameters were calculated using a noncompartmental method. Geometric mean ratios (GMRs) of the test and reference formulations with 90% confidence intervals (90% CI) were estimated for PK parameters using a generalized linear mixed-effects model. The GMRs (with 90% CI) of the test and reference formulations for the maximum concentration of aceclofenac and the area under the plasma concentration versus time curve from 0 to the last measurable concentration were 0.994 (0.917-1.077) and 0.895 (0.859-0.932), respectively. Both formulations were well tolerated. The test formulation of aceclofenac was bioequivalent to the reference formulation and can be considered a therapeutic option for patients requiring aceclofenac treatment.

Key words: aceclofenac, bioequivalence, pharmacokinetics
Introduction

Aceclofenac, \((2-\{2-[(2,6\text{-Dichlorophenyl})amino]phenyl\}acetoxy)acetic\) acid, is an orally administered nonsteroidal anti-inflammatory drug (NSAID) used to treat painful rheumatic conditions (Reginster et al., 2001) such as rheumatoid arthritis and ankylosing spondylitis. It alleviates pain and reduces inflammation by inhibiting cyclooxygenase enzymes (Dugowson and Gnanashanmugam, 2006; Gonzalez et al., 1994), which prevents the production of prostaglandins (lipid compounds that cause pain, swelling, and inflammation at sites of injury or damage). Among all the NSAIDs, aceclofenac is particularly well tolerated (Pareek and Chandurkar, 2013), with a lower incidence of gastrointestinal adverse effects such as indigestion, heartburn, nausea, diarrhea, bleeding, and ulcers (Legrand, 2004; Raza et al., 2014).

The recommended dosage of aceclofenac for the symptomatic treatment of pain and inflammatory or degenerative arthropathies is 100 mg twice daily (Moore et al., 2009; Scheen, 1999). The time to reach maximum plasma concentration for aceclofenac \((T_{\text{max}})\) is 1.25 to 3 hours and the half-life \((t_{1/2})\) is 3.5 to 6.2 hours after oral administration, which necessitates dosing every 12 hours to maintain optimum levels of analgesia (Bae et al., 2012). The primary route of elimination of aceclofenac is the liver, with only one percent of the administered dose being excreted unchanged in the urine (Bort et al., 1996). It is metabolized via the CYP2C9 enzyme to 4-hydroxyaceclofenac, diclofenac, and 4'-hydroxydiclofenac, which are active metabolites that are further conjugated to inactive metabolites (Yamazaki et al., 1999). Reduced daily dosing is generally not needed in elderly patients or in those with mild renal impairment, but one study suggests dose reduction to half the daily dose (100 mg daily) in patients with hepatic impairment (Dooley et al., 2001).

Genetic variations of the CYP2C9 enzyme can lead to interpatient variability in pharmacokinetics (PKs) and efficacy (Lee et al., 2007). Several CYP2C9 single nucleotide polymorphisms (SNPs) such as CYP2C9*2 (rs1799853) or CYP2C9*3 (rs1057910) were associated with decreased CYP2C9 enzyme activity (Agundez et al., 2009; Chaudhry et al., 2014). Those genetic variations can alter the PK characteristics of NSAIDs (Lopez-Rodriguez et al., 2008), increasing the risk of developing acute gastrointestinal bleeding (Ma et al., 2008).

A Korean domestic pharmaceutical company has developed a new formulation of aceclofenac 100 mg. The aim of this study was to compare the PK properties of the two aceclofenac 100 mg tablet formulations and evaluate their bioequivalence.
Methods

Study design and subject selection

A randomized, single-dose, 2 × 2 crossover study was conducted on 26 healthy Korean male volunteers. Subjects randomly received either the test formulation of aceclofenac 100 mg (Afenac®, Korea Arlico pharm. Co., Ltd., Seoul, Korea) or 100 mg of the reference formulation (Airtal®, Dae Woong Pharmaceutical Co., Ltd., Seoul, Korea). After the initial dose, they underwent a 1 week washout and then crossed over. Subjects were hospitalized at the Clinical Trials Center of Kyung Hee University Hospital, Seoul, Korea, the day before drug administration. After an overnight fast, a single dose of the test or reference formulation of aceclofenac 100 mg was administered to the subjects with 240 ml of water. The subjects were under continuous medical supervision at the study site for the duration of the study, during which adverse events and vital signs were monitored to assess tolerability. This study was approved by the Institutional Review Boards of Kyung Hee University Hospital and was conducted in accordance with the Declaration of Helsinki (2014) and the International Conference on Harmonization Good Clinical Practice guidelines. All of the subjects who participated were informed of the aim and risks of the study by the clinical investigators, and all subjects provided written informed consent before participating.

Blood sample collection and determination of aceclofenac concentration

To analyze the plasma concentration of aceclofenac, serial blood samples were obtained using a lithium heparin-coated tube before dosing (0) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 hours after drug administration. All plasma samples were analyzed using validated high-performance liquid chromatography (HPLC) coupled with triple quadrupole tandem mass spectrometry (Agilent Technologies, Inc., Santa Clara, California, USA) (Srinivas, 2009). To prepare the samples for analysis, 100 µL of plasma specimen was mixed with 0.1% formic acid in acetonitrile (35:65, v/v) in the presence of an internal standard (ramipril). The mixture was vortexed for 1 min and then centrifuged for 8 min at 12,000 rpm. An aliquot of the supernatant was transferred to an autosampler vial and 1 µL was injected onto the Gemini C18 110A column (50 x 2.0 mm, 3 µm, Phenomena, Inc., Torrance, California, USA) at a flow rate of 0.2 mL/min using gradient elution. Detection of precursor-to-product ion transition was achieved by employing electrospray ionization in the positive ion...
mode along with multiple reactions monitoring (MRM). The precursor/product ion pair mass-to-charge ratio (m/z) for aceclofenac was 351.86/79.40. The calibration curves were linear over the range of 0.5-50 μg/mL. Interday precision and accuracy were determined by repeated analyses on 5 consecutive days using 0.5, 1, 20, and 50 μg/mL of aceclofenac. Intraday percent coefficients of variation (% CV) and accuracy were 1.95-6.58% and 96.84-104.92%, respectively. Interday % CV and accuracy were 4.00-7.03% and 98.97-101.22%, respectively.

**PK analysis**

The plasma concentration of aceclofenac was analyzed by noncompartmental analysis using Phoenix® WinNonlin® software version 6.3 (Certara, St. Louis, MO, USA). Area under the plasma concentration versus time curve from 0 h to the last measurable concentration (AUC_{last}) was calculated using the linear trapezoidal method. The observed concentrations and times were used to estimate the maximum plasma concentration (C_{max}), and time required to reach the maximum plasma concentration (T_{max}). The apparent terminal elimination rate constant (λ_{z}) was estimated from regression of log-transformed plasma concentration of aceclofenac versus time over the terminal log-linear disposition portion of the concentration-time profiles, and the elimination half-life (t_{1/2}) was calculated as \( t_{1/2} = \ln 2 / \lambda_z \). Total apparent clearance (CL/F, where CL is clearance and F is the bioavailability) of aceclofenac was calculated as the administered dose (100 mg) divided by the AUC_{last}, and the apparent volume of distribution (V_{z}/F, where V_{z} is the volume of distribution and F is the bioavailability) was calculated as CL/F divided by λ_{z}.

**Statistical analysis**

We calculated the arithmetic mean and standard deviation (SD) for every demographic characteristic and PK parameter. To compare the bioavailability of the test and reference formulations, a generalized linear mixed effects model was developed for log(AUC_{last}) and log(C_{max}), with period, sequence, and treatment as fixed effects and subjects nested in sequence as random effects. Using this model, the geometric mean ratios (test/reference) with a 90% confidence interval for AUC_{last} and C_{max} were calculated. Bioequivalence was concluded if the GMRs and 90% CIs for AUC_{last} and C_{max} fell within range of 0.80 to 1.25, as proposed by the
Ministry of Food and Drug Safety of Korea. Statistical analyses were performed using SAS software version 9.3 (SAS Institute Inc., Cary, NC, USA).
Results

Subjects

A total of 26 healthy male subjects were enrolled in this study. Three of them withdrew consent before drug administration in the first period. This left a total of 23 subjects to complete the study as planned. Mean subject age, height, and weight (with standard deviations) were 24.83 (3.83) years, 174.07 (5.60) cm, and 71.45 (12.80) kg, respectively. Age, height, and weight were not statistically different between sequence groups.

Pharmacokinetics

Systemic exposure to aceclofenac after a single oral administration of the test formulation was similar to that of the reference formulation. The mean plasma concentration versus time curves for the test and reference drugs were similar (Figure 1). The GMRs with 90% CIs for $\text{AUC}_{\text{last}}$ and $\text{C}_{\text{max}}$ were within the range of 0.8 to 1.25 (Table 1), which satisfies the conventional regulatory criteria for bioequivalence. No trend was found in individual comparisons between the test and reference formulations for $\text{AUC}_{\text{last}}$ and $\text{C}_{\text{max}}$ (Figure 2). Other PK parameters, including $t_{\text{max}}$, $t_{1/2}$, CL/F, and $V_z$/F, were also comparable between the test and reference formulations (Table 1).

Tolerability

Aceclofenac was well tolerated by all of the volunteers, with no clinically significant adverse events related to aceclofenac administration reported. All vital signs and physical examinations assessed during the study period did not reveal anything clinically significant.
Discussion

The results indicate that the newly developed aceclofenac 100 mg tablet formulation has a PK and tolerability profile that is comparable to the reference formulation. The GMRs with a 90% CI for AUC_{last} and C_{max} were entirely within the conventionally accepted range for bioequivalence (0.8 to 1.25). The mean plasma concentration versus time curves for the two formulations were superimposable (Figure 1), and no systemic deviations were found for individual comparisons of AUC_{last} and C_{max} (Figure 2). Both the formulations were well tolerated by healthy volunteers after a single oral administration.

This study’s design was adequate for comparing the PK characteristics of the test and reference formulations of aceclofenac. The blood sampling time points were adequate for observing the C_{max} of aceclofenac (0 to 2 hours). The 12-hour sampling from each dosing (more than 10-fold longer than the t_{1/2}) was long enough to assess the elimination phase of aceclofenac. To avoid a carry-over effect, the washout period lasted 10-fold longer than the t_{1/2}, so that no measurable plasma concentration was detected in any of the subjects before dosing in the second period. The number of subjects was adequate to show the bioequivalence of the test and reference aceclofenac formulations, with a post hoc power analysis revealing that the actual statistical power of our study was greater than 99%.

The PK parameters observed in this study differed from those reported in an earlier study performed on Indian subjects, but genetic variation of the \textit{CYP2C9} might explain this difference. After Indian subjects ingested a single oral dose of aceclofenac 100 mg, the mean AUC_{last} and t_{1/2} were calculated to be 27.52 to 28.46 µg·h·mL^{-1} and 2.83 to 3.06 hours, respectively; whereas the corresponding parameters in this study were 22.26 to 23.96 µg·h·mL^{-1} and 1.1 to 1.2 hours, respectively (Gowda \textit{et al.}, 2006). The minor allele frequencies of \textit{CYP2C9*2} and \textit{CYP2C9*3} SNPs in Indians were 7% and 9%, respectively (Bhatt \textit{et al.}, 2014), and approximately 0% and 3.2%, respectively, in Koreans. Therefore, a proportionately greater number of Indians would have decreased \textit{CYP2C9} enzymatic activity, with a corresponding decreased ability to metabolize aceclofenac compared to Koreans (Martinez \textit{et al.}, 2006; Myrand \textit{et al.}, 2008). We believe the decreased enzymatic activity of \textit{CYP2C9} SNP (Falzoi \textit{et al.}, 2010) in Indian subjects resulted in higher AUC_{last} and t_{1/2} values than that observed in the Korean subjects of this study. The PK parameters we calculated were comparable to those of a previous study performed in healthy Korean subjects, and our data supports the observation of the interethnic variability of aceclofenac PK (Llerena \textit{et al.}, 2014).
We conclude that the test formulation of aceclofenac 100 mg tablet is bioequivalent to the reference formulation.
References


Table 1. Comparison of pharmacokinetic parameters between the two aceclofenac 100 mg formulations (test and reference) after single oral administration

<table>
<thead>
<tr>
<th>PK parameters</th>
<th>Test (Afenac®, N=23)</th>
<th>Reference (Airtal®, N=23)</th>
<th>GMR²</th>
<th>Intrasubject</th>
<th>Intersubject</th>
</tr>
</thead>
<tbody>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt; (µg/mL)</td>
<td>11.02 ± 3.23</td>
<td>10.95 ± 2.86</td>
<td>0.994 (0.917-1.077)</td>
<td>15.95</td>
<td>24.55</td>
</tr>
<tr>
<td>AUC&lt;sub&gt;last&lt;/sub&gt; (µg·h·mL&lt;sup&gt;-1&lt;/sup&gt;)</td>
<td>22.26 ± 8.48</td>
<td>23.96 ± 7.71</td>
<td>0.895 (0.859-0.932)</td>
<td>9.06</td>
<td>35.51</td>
</tr>
<tr>
<td>T&lt;sub&gt;max&lt;/sub&gt;¹ (h)</td>
<td>2.2 [1.0-4.0]</td>
<td>2.1 [1.0-4.0]</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CL/F (ml/h)</td>
<td>4626.21 ± 1867.89</td>
<td>4341.85 ± 1472.94</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vz/F (ml)</td>
<td>6527.86 ± 777.88</td>
<td>6800.73 ± 1528.54</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>t&lt;sub&gt;1/2&lt;/sub&gt; (h)</td>
<td>1.1 ± 0.4</td>
<td>1.2 ± 0.4</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

T<sub>max</sub>, time to reach the maximum blood concentration after administration of drug; C<sub>max</sub>, maximum plasma concentration of drug; AUC<sub>last</sub>, area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration; t<sub>1/2</sub>, terminal elimination half-life; CL/F, apparent clearance; Vz/F, Apparent volume of distribution during terminal phase after non-intravenous administration.

C<sub>max</sub>, AUC<sub>last</sub>, CL/F, Vz/F and t<sub>1/2</sub> are presented as mean ± standard deviation

¹T<sub>max</sub> is presented as median [minimum-maximum]

²Geometric mean ratio
FIGURE LEGENDS

Figure 1. Mean plasma concentration-time profile of aceclofenac after a single oral administration of test (filled circle) and reference (open circle) formulation of aceclofenac 100 mg. The error bars denote the standard deviations.

Figure 2. Comparison of $C_{\text{max}}$ and AUC$_{\text{last}}$ between the two aceclofenac formulations (test and reference) in individual subjects.
Figure 1

Plasma concentration of aceclofenac (µg/mL)

Time (h)

Reference
Test

Plasma concentration of aceclofenac (µg/mL)

Time (h)
Figure 2

- Top graph: $C_{\text{max}}$ (µg/mL) against Reference and Test.
- Bottom graph: $AUC_{\text{test}}$ (h$\cdot$µg/mL) against Reference and Test.